The Feasibility of Median Sternotomy With or Without Thoracotomy for Locally Advanced Non-Small Cell Lung Cancer Treated With Induction Chemoradiotherapy

被引:6
|
作者
Sato, Hiroki
Toyooka, Shinichi
Soh, Junichi
Hotta, Katsuyuki
Katsui, Kuniaki
Yamamoto, Hiromasa
Sugimoto, Seiichiro
Oto, Takahiro
Kanazawa, Susumu
Kiura, Katsuyuki
Miyoshi, Shinichiro
机构
[1] Okayama Univ Hosp, Dept Thorac Surg, Okayama, Japan
[2] Okayama Univ Hosp, Dept Clin Genom Med, Okayama, Japan
[3] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[4] Okayama Univ Hosp, Dept Radiol, Okayama, Japan
来源
ANNALS OF THORACIC SURGERY | 2016年 / 102卷 / 03期
关键词
PULMONARY RESECTION; CONCURRENT CHEMORADIOTHERAPY; SURGICAL RESECTION; CARINAL RESECTION; PHASE-III; CHEMOTHERAPY; CISPLATIN; RADIATION; DOCETAXEL; SURGERY;
D O I
10.1016/j.athoracsur.2016.03.092
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. This study aimed to compare the morbidity and mortality of a median sternotomy approach and a lateral thoracotomy and to investigate the feasibility of a median sternotomy for locally advanced non-small cell lung cancer (NSCLC) after induction chemoradiotherapy. Methods. The medical records of patients with locally advanced NSCLC who underwent induction chemoradiotherapy followed by surgery at our institution between January 1999 and September 2014 were reviewed. We compared the morbidity and mortality of a median sternotomy approach and a lateral thoracotomy. Results. A total of 102 NSCLC patients were the subjects of this study. Among them, 31 patients underwent surgery with a median sternotomy approach and 71 patients underwent surgery with a lateral thoracotomy. Patients in the median sternotomy group had a significantly higher rate of postoperative arrhythmia than those in the lateral thoracotomy group (p = 0.0028). However, all the complications were manageable, and no treatment-related deaths occurred in the median sternotomy group. Regarding the prognosis, the 5-year overall survival rate was 72.7%, and the 2-year recurrence-free survival rate was 66.5% in the entire population. No significant differences in overall survival or recurrence-free survival were observed between the 2 approaches. Conclusions. Whereas the lateral thoracotomy approach is a standard procedure, our experience suggests that a median sternotomy approach for locally advanced NSCLC after induction chemoradiotherapy is a feasible procedure and can be a surgical option. (C) 2016 by The Society of Thoracic Surgeons
引用
收藏
页码:985 / 992
页数:8
相关论文
共 50 条
  • [21] Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non-Small Cell Lung Cancer: The Induction Trial
    Smeenk, Michiel M.
    van Diessen, Judi N. A.
    Boellaard, Thierry N.
    Hartemink, Koen J.
    de Vries, Jeltje F.
    van der Noort, Vincent
    Badrising, Sushil K.
    Owers, Emilia C.
    Monkhorst, Kim
    van den Heuvel, Michel M.
    Theelen, Willemijn S. M. E.
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 1037 - 1046
  • [22] Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer
    Byrne, MJ
    Phillips, M
    Powell, A
    Cameron, F
    Joseph, D
    Spry, N
    Dewar, J
    Van Hazel, G
    Buck, M
    Lund, H
    De Melker, Y
    Newman, M
    INTERNAL MEDICINE JOURNAL, 2005, 35 (06) : 336 - 342
  • [23] Impact of induction chemotherapy prior to chemoradiotherapy on survival in patients with locally advanced non-small cell lung cancer (NSCLC)
    Ozkan, A.
    Kocak, M.
    Mayadagli, A.
    Parlak, C.
    Demir, O.
    Marti, A.
    Yilmaz, A.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S389 - S390
  • [24] Impact of sarcopenia on the outcome of patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy followed by durvalumab
    Tamura, K.
    Horinouchi, H.
    Miyake, M.
    Masuda, K.
    Shinno, Y.
    Okuma, Y.
    Yoshida, T.
    Goto, Y.
    Yamamoto, N.
    Ohe, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1659 - S1659
  • [25] Radiomics Nomogram for Predicting Locoregional Failure in Locally Advanced Non-small Cell Lung Cancer Treated with Definitive Chemoradiotherapy
    Chen, X.
    Tong, X.
    Qiu, Q.
    Sun, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S172 - S172
  • [26] Assessment of radiation pneumonitis and predictive factors in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
    Gunnarsson, Kerstin
    Movik, Louise
    Pettersson, Niclas
    Back, Anna
    Nyman, Jan
    Hallqvist, Andreas
    ACTA ONCOLOGICA, 2024, 63 : 791 - 797
  • [27] Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy
    Masami Ito
    Seiji Niho
    Keiji Nihei
    Kiyotaka Yoh
    Hironobu Ohmatsu
    Yuichiro Ohe
    BMC Cancer, 12
  • [28] Prediction of Clinical Outcome in Locally Advanced Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy by Plasma Markers
    Sui, Xin
    Jiang, Leilei
    Teng, Huajing
    Mi, Lan
    Li, Bo
    Shi, Anhui
    Yu, Rong
    Li, Dongming
    Dong, Xin
    Yang, Dan
    Yu, Huiming
    Wang, Weihu
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [29] IMPACT OF PRETRETMENT LEUKOCYTOSIS ON PROGNOSIS IN LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS TREATED WITH CONCURRENT CHEMORADIOTHERAPY
    Topkan, Erkan
    Parlak, Cem
    Pehlivan, Berrin
    Ozyilkan, Ozgur
    Selek, Ugur
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S556 - S556
  • [30] Radiomics Nomogram for Predicting Locoregional Failure in Locally Advanced Non-small Cell Lung Cancer Treated with Definitive Chemoradiotherapy
    Chen, Xia
    Tong, Xin
    Qiu, Qingtao
    Sun, Fenghao
    Yin, Yong
    Gong, Guanzhong
    Xing, Ligang
    Sun, Xiaorong
    ACADEMIC RADIOLOGY, 2022, 29 : S53 - S61